dextroamphetamine potent central nervous system cns stimulant enantiomernote amphetamine prescribed treatment attention deficit hyperactivity disorder adhd also used athletic performance cognitive enhancer recreationally aphrodisiac euphoriant amphetamine molecule exists two enantiomersnote levoamphetamine dextroamphetamine dextroamphetamine dextrorotatory righthanded enantiomer exhibits pronounced effects central nervous system levoamphetamine pharmaceutical dextroamphetamine sulfate available brand name generic drug variety dosage forms dextroamphetamine sometimes prescribed inactive prodrug lisdexamfetamine dimesylate converted dextroamphetamine absorption dextroamphetamine like amphetamines elicits stimulating effects via several distinct actions inhibits reverses transporter proteins monoamine neurotransmitters namely serotonin norepinephrine dopamine transporters either via trace amineassociated receptor independent fashion high cytosolic concentrations monoamine releases neurotransmitters synaptic vesicles via vesicular monoamine transporter also shares many chemical pharmacological properties human trace amines particularly phenethylamine nmethylphenethylamine latter isomer amphetamine produced within human body dextroamphetamine used treat attention deficit hyperactivity disorder adhd narcolepsy sleep sometimes prescribed offlabel depression longterm amphetamine exposure sufficiently high doses animal species known produce abnormal dopamine system development nerve humans adhd longterm use pharmaceutical amphetamines therapeutic doses appears improve brain development nerve reviews magnetic resonance imaging mri studies suggest longterm treatment amphetamine decreases abnormalities brain structure function found subjects adhd improves function several parts brain right caudate nucleus basal reviews clinical stimulant research established safety effectiveness longterm continuous amphetamine use treatment randomized controlled trials continuous stimulant therapy treatment adhd spanning years demonstrated treatment effectiveness two reviews indicated longterm continuous stimulant therapy adhd effective reducing core symptoms adhd ie hyperactivity inattention impulsivity enhancing quality life academic achievement producing improvements large number functional outcomesnote across categories outcomes related academics antisocial behavior driving nonmedicinal drug use obesity occupation selfesteem service use ie academic occupational health financial legal services social one review highlighted ninemonth randomized controlled trial amphetamine treatment adhd children found average increase iq points continued increases attention continued decreases disruptive behaviors another review indicated based upon longest followup studies conducted date lifetime stimulant therapy begins childhood continuously effective controlling adhd symptoms reduces risk developing substance use disorder current models adhd suggest associated functional impairments brains neurotransmitter functional impairments involve impaired dopamine neurotransmission mesocorticolimbic projection norepinephrine neurotransmission noradrenergic projections locus coeruleus prefrontal psychostimulants like methylphenidate amphetamine effective treating adhd increase neurotransmitter activity approximately use stimulants see improvements adhd children adhd use stimulant medications generally better relationships peers family members perform better school less distractible impulsive longer attention cochrane reviewsnote treatment adhd children adolescents adults pharmaceutical amphetamines stated shortterm studies demonstrated drugs decrease severity symptoms higher discontinuation rates nonstimulant medications due adverse side cochrane review treatment adhd children tic disorders tourette syndrome indicated stimulants general make tics worse high doses dextroamphetamine could exacerbate tics systematic review metaanalysis high quality clinical trials found used low therapeutic doses amphetamine produces modest yet unambiguous improvements cognition including working memory longterm episodic memory inhibitory control aspects attention normal healthy cognitionenhancing effects amphetamine known partially mediated indirect activation dopamine receptor adrenoceptor prefrontal systematic review found low doses amphetamine also improve memory consolidation turn leading improved recall therapeutic doses amphetamine also enhance cortical network efficiency effect mediates improvements working memory amphetamine adhd stimulants also improve task saliency motivation perform task increase arousal wakefulness turn promoting goaldirected stimulants amphetamine improve performance difficult boring tasks used students study testtaking based upon studies selfreported illicit stimulant use college students use diverted adhd stimulants primarily used enhancement academic performance rather recreational however high amphetamine doses therapeutic range interfere working memory aspects cognitive amphetamine used athletes psychological athletic performanceenhancing effects increased endurance however nonmedical amphetamine use prohibited sporting events regulated collegiate national international antidoping healthy people oral therapeutic doses amphetamine shown increase muscle strength acceleration athletic performance anaerobic conditions endurance ie delays onset fatigue improving reaction amphetamine improves endurance reaction time primarily reuptake inhibition release dopamine central nervous amphetamine dopaminergic drugs also increase power output fixed levels perceived exertion overriding safety switch allowing core temperature limit increase order access reserve capacity normally therapeutic doses adverse effects amphetamine impede athletic however much higher doses amphetamine induce effects severely impair performance rapid muscle breakdown elevated body dextroamphetamine also used recreationally euphoriant aphrodisiac like amphetamines used club drug energetic euphoric high dextroamphetamine considered high potential misuse recreational manner since individuals typically report feeling euphoric alert energetic taking dextroamphetamines dopaminergic rewarding properties affect mesocorticolimbic circuit group neural structures responsible incentive salience ie wanting desire craving reward motivation positive reinforcement positivelyvalenced emotions particularly ones involving large recreational doses dextroamphetamine may produce symptoms dextroamphetamine recreational users sometimes open dexedrine capsules crush contents order insufflate snort subsequently dissolve water inject immediaterelease formulations higher potential abuse via insufflation snorting intravenous injection due favorable pharmacokinetic profile easy crushability especially reason using crushed spansules insufflation injection methods evidently due instantrelease forms drug seen tablet preparations often containing sizable amount inactive binders fillers alongside active damphetamine injection bloodstream dangerous insoluble fillers within tablets block small blood chronic overuse dextroamphetamine lead severe drug dependence resulting withdrawal symptoms drug use according international programme chemical safety ipcs united states food drug administration usfdanote amphetamine contraindicated people history drug abusenote cardiovascular disease severe agitation severe also contraindicated individuals advanced arteriosclerosis hardening arteries glaucoma increased eye pressure hyperthyroidism excessive production thyroid hormone moderate severe agencies indicate people experienced allergic reactions stimulants taking monoamine oxidase inhibitors maois take although safe concurrent use amphetamine monoamine oxidase inhibitors agencies also state anyone anorexia nervosa bipolar disorder depression hypertension liver kidney problems mania psychosis raynauds phenomenon seizures thyroid problems tics tourette syndrome monitor symptoms taking evidence human studies indicates therapeutic amphetamine use cause developmental abnormalities fetus newborns ie human teratogen amphetamine abuse pose risks amphetamine also shown pass breast milk ipcs usfda advise mothers avoid breastfeeding using due potential reversible growth impairmentsnote usfda advises monitoring height weight children adolescents prescribed amphetamine cardiovascular side effects include hypertension hypotension vasovagal response raynauds phenomenon reduced blood flow hands feet tachycardia increased heart sexual side effects males may include erectile dysfunction frequent erections prolonged gastrointestinal side effects may include abdominal pain constipation diarrhea potential physical side effects include appetite loss blurred vision dry mouth excessive grinding teeth nosebleed profuse sweating rhinitis medicamentosa druginduced nasal congestion reduced seizure threshold tics type movement disorder weight losssources dangerous physical side effects rare typical pharmaceutical amphetamine stimulates medullary respiratory centers producing faster deeper normal person therapeutic doses effect usually noticeable respiration already compromised may amphetamine also induces contraction urinary bladder sphincter muscle controls urination result difficulty effect useful treating bed wetting loss bladder effects amphetamine gastrointestinal tract intestinal activity high amphetamine may reduce gastrointestinal motility rate content moves digestive however amphetamine may increase motility smooth muscle tract amphetamine also slight analgesic effect enhance pain relieving effects usfdacommissioned studies indicate children young adults adults association serious adverse cardiovascular events sudden death heart attack stroke medical use amphetamine adhd stimulantssources however amphetamine pharmaceuticals contraindicated individuals cardiovascular diseasesources normal therapeutic doses common psychological side effects amphetamine include increased alertness apprehension concentration initiative selfconfidence sociability mood swings elated mood followed mildly depressed mood insomnia wakefulness decreased sense less common side effects include anxiety change libido grandiosity irritability repetitive obsessive behaviors restlessnesssources effects depend users personality current mental amphetamine psychosis eg delusions paranoia occur heavy although rare psychosis also occur therapeutic doses longterm according usfda systematic evidence stimulants produce aggressive behavior amphetamine also shown produce conditioned place preference humans taking therapeutic meaning individuals acquire preference spending time places previously used addiction serious risk heavy recreational amphetamine use unlikely occur longterm medical use therapeutic fact lifetime stimulant therapy adhd begins childhood reduces risk developing substance use disorders pathological overactivation mesolimbic pathway dopamine pathway connects ventral tegmental area nucleus accumbens plays central role amphetamine individuals frequently selfadminister high doses amphetamine high risk developing amphetamine addiction since chronic use high doses gradually increases level accumbal δfosb molecular switch master control protein nucleus accumbens δfosb sufficiently overexpressed begins increase severity addictive behavior ie compulsive drugseeking increases currently effective drugs treating amphetamine addiction regularly engaging sustained aerobic exercise appears reduce risk developing exercise therapy improves clinical treatment outcomes may used adjunct therapy behavioral therapies chronic use amphetamine excessive doses causes alterations gene expression mesocorticolimbic projection arise transcriptional epigenetic important transcription factorsnote produce alterations delta fbj murine osteosarcoma viral oncogene homolog b δfosb camp response element binding protein creb nuclear factorkappa b δfosb significant biomolecular mechanism addiction δfosb overexpression ie abnormally high level gene expression produces pronounced generelated phenotype medium spiny neurons nucleus accumbens necessary sufficientnote many neural adaptations regulates multiple behavioral effects eg reward sensitization escalating drug selfadministration involved δfosb sufficiently overexpressed induces addictive state becomes increasingly severe increases δfosb implicated addictions alcohol cannabinoids cocaine methylphenidate nicotine opioids phencyclidine propofol substituted amphetamines among otherssources δjund transcription factor histone methyltransferase enzyme oppose function δfosb inhibit increases sufficiently overexpressing δjund nucleus accumbens viral vectors completely block many neural behavioral alterations seen chronic drug abuse ie alterations mediated similarly accumbal hyperexpression results markedly increased histone lysine residue dimethylation blocks induction δfosbmediated neural behavioral plasticity chronic drug usesources occurs via repression transcription factors δfosb repression various δfosb transcriptional targets eg δfosb also plays important role regulating behavioral responses natural rewards palatable food sex since natural rewards addictive drugs induce expression δfosb ie cause brain produce chronic acquisition rewards result similar pathological state consequently δfosb significant factor involved amphetamine addiction amphetamineinduced sexual addictions compulsive sexual behaviors result excessive sexual activity amphetamine sexual addictions associated dopamine dysregulation syndrome occurs patients taking dopaminergic effects amphetamine gene regulation dose research gene regulation addiction based upon animal studies intravenous amphetamine administration high studies used equivalent weightadjusted human therapeutic doses oral administration show changes occur relatively suggests medical use amphetamine significantly affect gene december effective pharmacotherapy amphetamine reviews indicated agonists significant therapeutic potential treatment psychostimulant however february compounds known function agonists experimental amphetamine addiction largely mediated increased activation dopamine receptors colocalized nmda receptorsnote nucleus magnesium ions inhibit nmda receptors blocking receptor calcium one review suggested based upon animal testing pathological addictioninducing psychostimulant use significantly reduces level intracellular magnesium throughout supplemental magnesiumnote treatment shown reduce amphetamine selfadministration ie doses given oneself humans effective monotherapy amphetamine systematic review metaanalysis assessed efficacy different pharmacotherapies used randomized controlled trials rcts amphetamine methamphetamine found lowstrength evidence methylphenidate might reduce amphetamine methamphetamine low moderatestrength evidence benefit medications used rcts included antidepressants bupropion mirtazapine sertraline antipsychotics aripiprazole anticonvulsants topiramate baclofen gabapentin naltrexone varenicline citicoline ondansetron prometa riluzole atomoxetine dextroamphetamine systematic review network metaanalysis trials involving different psychosocial interventions amphetamine methamphetamine cocaine addiction found combination therapy contingency management community reinforcement approach highest efficacy ie abstinence rate acceptability ie lowest dropout treatment modalities examined analysis included monotherapy contingency management community reinforcement approach cognitive behavioral therapy programs noncontingent rewardbased therapies psychodynamic therapy combination therapies involving additionally research neurobiological effects physical exercise suggests daily aerobic exercise especially endurance exercise eg marathon running prevents development drug addiction effective adjunct therapy ie supplemental treatment amphetamine addictionsources exercise leads better treatment outcomes used adjunct treatment particularly psychostimulant particular aerobic exercise decreases psychostimulant selfadministration reduces reinstatement ie relapse drugseeking induces increased dopamine receptor density opposite pathological stimulant use induces decreased striatal one review noted exercise may also prevent development drug addiction altering δfosb cfos immunoreactivity striatum parts reward drug tolerance develops rapidly amphetamine abuse ie recreational amphetamine use periods extended abuse require increasingly larger doses drug order achieve according cochrane review withdrawal individuals compulsively use amphetamine methamphetamine chronic heavy users abruptly discontinue amphetamine use many report timelimited withdrawal syndrome occurs within hours last review noted withdrawal symptoms chronic highdose users frequent occurring roughly cases persist weeks marked crash phase occurring first amphetamine withdrawal symptoms include anxiety drug craving depressed mood fatigue increased appetite increased movement decreased movement lack motivation sleeplessness sleepiness lucid review indicated severity withdrawal symptoms positively correlated age individual extent mild withdrawal symptoms discontinuation amphetamine treatment therapeutic doses avoided tapering amphetamine overdose lead many different symptoms rarely fatal appropriate severity overdose symptoms increases dosage decreases drug tolerance tolerant individuals known take much grams amphetamine day roughly times maximum daily therapeutic symptoms moderate extremely large overdose listed fatal amphetamine poisoning usually also involves convulsions overdose amphetamine methamphetamine compounds implicated amphetamine use disorder resulted estimated deaths worldwide deaths confidencenote rodents primates sufficiently high doses amphetamine cause dopaminergic neurotoxicity damage dopamine neurons characterized dopamine terminal degeneration reduced transporter receptor evidence amphetamine directly neurotoxic however large doses amphetamine may indirectly cause dopaminergic neurotoxicity result hyperpyrexia excessive formation reactive oxygen species increased autoxidation dopaminesources animal models neurotoxicity highdose amphetamine exposure indicate occurrence hyperpyrexia ie core body temperature necessary development amphetamineinduced prolonged elevations brain temperature likely promote development amphetamineinduced neurotoxicity laboratory animals facilitating production reactive oxygen species disrupting cellular protein function transiently increasing barrier amphetamine overdose result stimulant psychosis may involve variety symptoms delusions cochrane review treatment amphetamine dextroamphetamine methamphetamine psychosis states users fail recover according review least one trial shows antipsychotic medications effectively resolve symptoms acute amphetamine psychosis rarely arises therapeutic many types substances known interact amphetamine resulting altered drug action metabolism amphetamine interacting substance inhibitors enzymes metabolize amphetamine eg prolong elimination halflife meaning effects last amphetamine also interacts maois particularly monoamine oxidase inhibitors since maois amphetamine increase plasma catecholamines ie norepinephrine therefore concurrent use amphetamine modulates activity psychoactive drugs particular amphetamine may decrease effects sedatives depressants increase effects stimulants amphetamine may also decrease effects antihypertensives antipsychotics due effects blood pressure dopamine zinc supplementation may reduce minimum effective dose amphetamine used treatment adhdnote amphetamine enantiomers identified potent full agonists trace amineassociated receptor gpcr discovered important regulation monoaminergic systems activation increases camp production via adenylyl cyclase activation inhibits function dopamine transporter norepinephrine transporter serotonin transporter well inducing release monoamine neurotransmitters amphetamine enantiomers also substrates specific neuronal synaptic vesicle uptake transporter called amphetamine taken vesicle releases effluxes dopamine norepinephrine serotonin among monoamines cytosol dextroamphetamine dextrorotary enantiomer levoamphetamine levorotary enantiomer identical pharmacodynamics binding affinities biomolecular targets dextroamphetamine potent agonist consequently dextroamphetamine produces roughly three four times central nervous system cns stimulation however levoamphetamine slightly greater cardiovascular peripheral amphetamine similar structure function endogenous trace amines naturally occurring neuromodulator molecules produced human body among group closely related compounds phenethylamine parent compound amphetamine nmethylphenethylamine isomer amphetamine ie identical molecular humans phenethylamine produced directly lphenylalanine aromatic amino acid decarboxylase aadc enzyme converts ldopa dopamine turn nmethylphenethylamine metabolized phenethylamine phenylethanolamine nmethyltransferase enzyme metabolizes norepinephrine like amphetamine phenethylamine nmethylphenethylamine regulate monoamine neurotransmission via unlike amphetamine substances broken monoamine oxidase b therefore shorter halflife oral bioavailability amphetamine varies gastrointestinal well absorbed gut bioavailability typically amphetamine weak base pka consequently ph basic drug lipid soluble free base form absorbed lipidrich cell membranes gut conversely acidic ph means drug predominantly watersoluble cationic salt form less approximately amphetamine circulating bloodstream bound plasma following absorption amphetamine readily distributes tissues body high concentrations occurring cerebrospinal fluid brain halflives amphetamine enantiomers differ vary urine normal urine ph halflives dextroamphetamine levoamphetamine hours hours highly acidic urine reduce enantiomer halflives highly alkaline urine increase halflives immediaterelease extended release variants salts isomers reach peak plasma concentrations hours hours postdose amphetamine eliminated via kidneys drug excreted unchanged normal urinary urinary ph basic amphetamine free base form less urine ph abnormal urinary recovery amphetamine may range low high depending mostly upon whether urine basic acidic following oral administration amphetamine appears urine within roughly ingested amphetamine eliminated days last oral dopamine βhydroxylase dbh flavincontaining monooxygenase butyratecoa ligase xmligase glycine nacyltransferase glyat enzymes known metabolize amphetamine metabolites humanssources amphetamine variety excreted metabolic products including benzoic acid hippuric acid norephedrine among metabolites active sympathomimetics main metabolic pathways involve aromatic parahydroxylation aliphatic alpha betahydroxylation noxidation ndealkylation known metabolic pathways detectable metabolites metabolizing enzymes humans include following racemic amphetamine first synthesized chemical name phenylisopropylamine berlin romanian chemist lazar edeleanu widely marketed pharmaceutical company smith kline french known glaxosmithkline introduced form benzedrine inhaler use bronchodilator notably amphetamine contained benzedrine inhaler liquid freebasenote chloride sulfate salt three years later medical community became aware stimulant properties amphetamine specifically dextroamphetamine isomer smith kline french introduced tablets brand name united states dexedrine approved treat narcolepsy attention canada indications included epilepsy dextroamphetamine marketed various forms following decades primarily smith kline french several combination medications including mixture dextroamphetamine amobarbital barbiturate sold tradename dexamyl extended release capsule preparations containing dextroamphetamine also used world war ii treatment quickly became apparent dextroamphetamine amphetamines high potential misuse although heavily controlled comprehensive drug abuse prevention control act passed united states congress dextroamphetamine along sympathomimetics eventually classified schedule ii restrictive category possible drug governmentsanctioned recognized medical internationally available names amfedyn italy curban us obetrol switzerland simpamina italy dexedrinegsk us canada dexedrineucb united kingdom dextropa portugal stild became popular mod scene england early carried northern soul scene north england end october glaxosmithkline sold rights dexedrine spansule amedra pharmaceuticals subsidiary us air force uses dextroamphetamine one go pills given pilots long missions help remain focused alert conversely nogo pills used mission completed combat effects mission tarnak farm incident linked media reports use drug long term fatigued pilots military accept explanation citing lack similar incidents newer stimulant medications awakeness promoting agents different side effect profiles modafinil investigated sometimes issued dextroamphetamine available transdermal patch containing dextroamphetamine base brand name united states immediate release ir formulations dextroamphetamine sulfate available generically mg mg tablets marketed barr teva pharmaceutical industries mallinckrodt pharmaceuticals wilshire pharmaceuticals aurobindo pharmaceutical usa corepharma previous ir tablets sold brand names dexedrine dextrostat discontinued ir tablets became available brand name zenzedi offered mg mg mg mg mg mg mg dextroamphetamine sulfate also available controlledrelease cr capsule preparation strengths mg mg mg brand name dexedrine spansule generic versions marketed barr mallinckrodt bubblegum flavored oral solution available brand name procentra manufactured fsc pediatrics designed easier method administration children difficulty swallowing tablets ml contains mg conversion rate dextroamphetamine sulfate amphetamine free base australia dexamfetamine available bottles instant release mg tablets generic slow release dextroamphetamine preparations may compounded individual united kingdom available mg instant release sulfate tablets generic name dexamfetamine sulfate well mg mg strength tablets brand name amfexa also available generic dexamfetamine sulfate mgml oral sugarfree brand name dexedrine available united kingdom prior ucb pharma disinvesting product another pharmaceutical company auden dextroamphetamine active metabolite prodrug lisdexamfetamine llysinedextroamphetamine available brand name vyvanse elvanse european market venvanse brazil market lisdexamfetamine dimesylate dextroamphetamine liberated lisdexamfetamine enzymatically following contact red blood cells conversion ratelimited enzyme prevents high blood concentrations dextroamphetamine reduces lisdexamfetamines drug liking abuse potential clinical vyvanse marketed onceaday dosing provides slow release dextroamphetamine body vyvanse available capsules chewable tablets seven strengths mg mg mg mg mg mg mg conversion rate lisdexamfetamine dimesylate vyvanse dextroamphetamine base another pharmaceutical contains dextroamphetamine commonly known brand name available immediate release ir tablets extended release xr adderall contains equal amounts four amphetamine adderall total amphetamine base equivalence enantiomer ratio dextroamphetamine salts levoamphetamine salts amphetamine base content dextroamphetamine levoamphetamine note stimulants phenylethanolamine httpsenwikipediaorgwikidextroamphetamine